131 related articles for article (PubMed ID: 37872093)
1. [Fuzheng Huayu capsules reducing development of hepatocellular carcinoma in cirrhotic patients with chronic hepatitis B based on the ratio of neutrophils/lymphocytes].
Shi K; Hou J; Zhang Y; Bi YF; Wang XB
Zhonghua Gan Zang Bing Za Zhi; 2023 Sep; 31(9):969-973. PubMed ID: 37872093
[No Abstract] [Full Text] [Related]
2. Impact of Fuzheng Huayu tablet on antiviral effect of entecavir in patients with hepatitis B cirrhosis.
Cheng DY; Zhao ZM; Wan G; Zheng HW; Huang JQ; Liu CH; Xing HC
Hepatobiliary Pancreat Dis Int; 2022 Oct; 21(5):479-484. PubMed ID: 35346577
[TBL] [Abstract][Full Text] [Related]
3. [Effects of anti-liver fibrosis treatment on the occurrence of liver cancer in patients with hepatitis B-related liver cirrhosis].
Shi K; Zhang Q; Huang YY; Wang XB
Zhonghua Gan Zang Bing Za Zhi; 2021 Jul; 29(7):685-689. PubMed ID: 34371540
[No Abstract] [Full Text] [Related]
4. Neutrophil-lymphocyte ratio and the risk of hepatocellular carcinoma in patients with hepatitis B-caused cirrhosis.
Shi K; Li P; Xue D; Liu Y; Zhang Q; Ping R; Wang X
Eur J Gastroenterol Hepatol; 2021 Dec; 33(1S Suppl 1):e686-e692. PubMed ID: 34074986
[TBL] [Abstract][Full Text] [Related]
5. [Effect of Fuzheng Huayu capsules on survival rate of patients with liver cirrhosis].
Ge XJ; Zhao CQ; Xu LM
Zhonghua Gan Zang Bing Za Zhi; 2017 Nov; 25(11):834-840. PubMed ID: 29325277
[No Abstract] [Full Text] [Related]
6. [Clinical study of yiqi huoxue recipe in the treatment of liver fibrosis of chronic viral hepatitis].
Cui LY; Zhang XX; Cui P; Li WC; Zhang YG; Wang RQ; Zhao SX; Ren WG; Kong LL; Han F; Yuan XW; Liu LD; Zhang Y; Zhang QS; Kong L; Nan YM
Zhonghua Gan Zang Bing Za Zhi; 2020 May; 28(5):403-409. PubMed ID: 32536056
[No Abstract] [Full Text] [Related]
7. Risk of hepatocellular carcinoma in antiviral treatment-naïve chronic hepatitis B patients treated with entecavir or tenofovir disoproxil fumarate: a network meta-analysis.
Huang ZH; Lu GY; Qiu LX; Zhong GH; Huang Y; Yao XM; Liu XH; Huang SJ; Wu T; Yuan Q; Wang YB; Su YY; Zhang J; Xia NS
BMC Cancer; 2022 Mar; 22(1):287. PubMed ID: 35300634
[TBL] [Abstract][Full Text] [Related]
8. Beneficial Effects of Traditional Chinese Medicine Fuzheng Huayu on the Occurrence of Hepatocellular Carcinoma in Patients with Compensated Chronic Hepatitis B Cirrhosis Receiving Entecavir: A Multicenter Retrospective Cohort Study.
Fan H; Lei S; Zhao Z; Huang Y; Wang H; Liu X; Li X; Xu M; Zhang W; Sun K; Xing H; Mei Y; Huang J; Zhu C; Zhang K; Zong Y; Shen X; Xie Q; Liu C
J Clin Transl Hepatol; 2024 May; 12(5):505-515. PubMed ID: 38779515
[TBL] [Abstract][Full Text] [Related]
9. Long-term follow-up of cumulative incidence of hepatocellular carcinoma in hepatitis B virus patients without antiviral therapy.
Jiang XY; Huang B; Huang DP; Wei CS; Zhong WC; Peng DT; Huang FR; Tong GD
World J Gastroenterol; 2021 Mar; 27(11):1101-1116. PubMed ID: 33776376
[TBL] [Abstract][Full Text] [Related]
10. Impact of long-term tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in patients with chronic hepatitis B.
Kim WR; Loomba R; Berg T; Aguilar Schall RE; Yee LJ; Dinh PV; Flaherty JF; Martins EB; Therneau TM; Jacobson I; Fung S; Gurel S; Buti M; Marcellin P
Cancer; 2015 Oct; 121(20):3631-8. PubMed ID: 26177866
[TBL] [Abstract][Full Text] [Related]
11. [Higher proportion of hepatitis B-related hepatocellular carcinoma combined with metabolic diseases in patients receiving antiviral therapy].
Zhao Z; Wang KF; Chen L; You QH; Wu YY; Sun J
Zhonghua Gan Zang Bing Za Zhi; 2021 Apr; 29(4):344-349. PubMed ID: 33979961
[No Abstract] [Full Text] [Related]
12. [Antiviral and antifibrotic therapies reduce occurrence of hepatocellular carcinoma in patients with chronic hepatitis B and liver fibrosis: a 144-week prospective cohort study].
Zhou Y; Hu C; Yuan G; Liu J; Ren Y; Tang C; Yang S; Dai L; Li Y; Yang D
Nan Fang Yi Ke Da Xue Xue Bao; 2019 Jun; 39(6):633-640. PubMed ID: 31270040
[TBL] [Abstract][Full Text] [Related]
13. Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B.
Papatheodoridis GV; Dalekos GN; Idilman R; Sypsa V; Van Boemmel F; Buti M; Calleja JL; Goulis J; Manolakopoulos S; Loglio A; Papatheodoridi M; Gatselis N; Veelken R; Lopez-Gomez M; Hansen BE; Savvidou S; Kourikou A; Vlachogiannakos J; Galanis K; Yurdaydin C; Esteban R; Janssen HLA; Berg T; Lampertico P
J Hepatol; 2020 Nov; 73(5):1037-1045. PubMed ID: 32553667
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the Efficacy of Entecavir and Tenofovir in Reducing Hepatocellular Carcinoma Risk in Chronic Hepatitis B Patients: A Real-Life Study in Turkey.
Güzelbulut F; Gökçen P; Can G; Adalı G; Değirmenci Saltürk AG; Aslan E; Özdil K; Doğanay HL
Turk J Gastroenterol; 2021 Apr; 32(4):412-421. PubMed ID: 34231488
[TBL] [Abstract][Full Text] [Related]
15. Delayed viral suppression during antiviral therapy is associated with increased hepatocellular carcinoma rates in HBeAg-positive high viral load chronic hepatitis B.
Nam JY; Chang Y; Cho H; Kang SH; Cho YY; Cho EJ; Lee JH; Yu SJ; Yoon JH; Kim YJ
J Viral Hepat; 2018 May; 25(5):552-560. PubMed ID: 29194870
[TBL] [Abstract][Full Text] [Related]
16. Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B.
Papatheodoridis GV; Sypsa V; Dalekos GN; Yurdaydin C; Van Boemmel F; Buti M; Calleja JL; Chi H; Goulis J; Manolakopoulos S; Loglio A; Voulgaris T; Gatselis N; Keskin O; Veelken R; Lopez-Gomez M; Hansen BE; Savvidou S; Kourikou A; Vlachogiannakos J; Galanis K; Idilman R; Esteban R; Janssen HLA; Berg T; Lampertico P
J Hepatol; 2020 Jun; 72(6):1088-1096. PubMed ID: 31981727
[TBL] [Abstract][Full Text] [Related]
17. Impact of tenofovir alafenamide vs. entecavir on hepatocellular carcinoma risk in patients with chronic hepatitis B.
Lee HW; Cho YY; Lee H; Lee JS; Kim SU; Park JY; Kim DY; Ahn SH; Kim BK; Park SY
Hepatol Int; 2021 Oct; 15(5):1083-1092. PubMed ID: 34402025
[TBL] [Abstract][Full Text] [Related]
18. Magnitude of and prediction for risk of hepatocellular carcinoma in patients with chronic hepatitis B taking entecavir or tenofovir therapy: A systematic review.
Tseng CH; Tseng CM; Wu JL; Hsu YC; El-Serag HB
J Gastroenterol Hepatol; 2020 Oct; 35(10):1684-1693. PubMed ID: 32343431
[TBL] [Abstract][Full Text] [Related]
19. Effective viral suppression is necessary to reduce hepatocellular carcinoma development in cirrhotic patients with chronic hepatitis B: Results of a 10-year follow up.
Zhang W; Wang X; Wang Y; Zhao X; Duan W; Wang Q; Wu X; Kong Y; Ma H; You H; Ou X; Jia J
Medicine (Baltimore); 2017 Nov; 96(44):e8454. PubMed ID: 29095292
[TBL] [Abstract][Full Text] [Related]
20. [Risk factors for the development of liver cancer in patients with hepatitis B-related liver cirrhosis treated with long-term nucleos(t)ide analogues].
Zang WW; Su MH; Ling XZ; Wang RM; Cao BC; Wu YL; Deng DL; Wei HL; Liang XS; Jiang JN
Zhonghua Gan Zang Bing Za Zhi; 2020 Aug; 28(8):679-685. PubMed ID: 32911907
[No Abstract] [Full Text] [Related]
[Next] [New Search]
